<u>,                                     </u>		<u> </u>
Notice of Allowability	Application No.	Applicant(s)
	09/762,602	KAROUZAKIS ET AL.
	Examin r	Art Unit
	San-ming Hui	1617
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT F of the Office or upon petition by the applicant. See 37 CFR 1.31	S (OR REMAINS) CLOSED in i) or other appropriate communication is second in the communication is second in the communication in the communication is second in the communication	this application. If not included unication will be mailed in due course. <b>THIS</b>
1. This communication is responsive to		
2. The allowed claim(s) is/are <u>27-31,33-42 and 48-57</u> .		
3.   The drawings filed on are accepted by the Examin	er.	
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority of a) ☐ All b) ☐ Some* c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority documents have a copies of the certified copies of the priority documents have a copies of the certified copies of the priority documents have a copies of the certified copies of the priority documents have a copies of the certified copies of the priority documents have a copies of the certified copies of the priority documents have a copies of the certified copies of the priority documents have a copies</li></ul>	re been received. re been received in Applicatio	n No
Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		a reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be subriNFORMAL PATENT APPLICATION (PTO-152) which give	mitted. Note the attached EXA ves reason(s) why the oath or	MINER'S AMENDMENT or NOTICE OF declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") mu  (a) including changes required by the Notice of Draftsper  1) hereto or 2) to Paper No./Mail Date  (b) including changes required by the attached Examiner  Paper No./Mail Date  Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in	rson's Patent Drawing Review  -  r's Amendment / Comment or  1.84(c)) should be written on th	in the Office action of
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	OSIT OF BIOLOGICAL MATE FOR THE DEPOSIT OF BIO	ERIAL must be submitted. Note the DLOGICAL MATERIAL.
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO-1449 or PTO/SB/Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. Interview Su Paper No./ (08), 7. Examiner's	formal Patent Application (PTO-152)  ummary (PTO-413),  Mail Date  Amendment/Comment  Statement of Reasons for Allowance

Application/Control Number: 09/762,602

Art Unit: 1617

## **DETAILED ACTION**

Applicant's response filed November 19, 2004 have been entered.

## **REASON FOR ALLOWANCE**

The following is an examiner's statement of reasons for allowance: The arguments present in the response filed November 19, 2004 have been considered, and are persuasive to withdraw the outstanding rejection under 35 USC 103. In particular, the cited prior art do not teach or fairly suggest the selection of misoprostol among a laundry list of female sexual dysfunction treatment agents. The information provided by the applicant in December 17, 2003 have been reconsidered. It is pointed out that some of the other female sexual dysfunction treatment agents disclosed in Nahoum, such as sildenafil and yohimbine, are not effective in treating female sexual dysfunction. therefore, there is no reason to select misoprostol out of a laundry list of compounds to treat female sexual dysfunction as claimed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Claims 27-31, 33-42, and 48-57 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to San-ming Hui whose telephone number is (571) 272-

Application/Control Number: 09/762,602

Art Unit: 1617

0626. The examiner can normally be reached on Mon 9:00 to 1:00, Tu - Fri from 9:00 to

6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, PhD., can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner

Page 3

Art Unit 1617